Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares 7-10 Year Treasury Bond ETF (IEF) vs Merck & Co., Inc. (MRK) Price & Performance

iShares 7-10 Year Treasury Bond ETFTrade
Merck & Co., Inc.Trade

Price performance (Past 24H)

Key statistics

iShares 7-10 Year Treasury Bond ETF vs Merck & Co., Inc. — how do they compare? iShares 7-10 Year Treasury Bond ETF trades at $93.11, while Merck & Co., Inc. trades at $129.91 (market cap $321.77B). The key difference: Merck & Co., Inc. pays a 2.61% dividend while iShares 7-10 Year Treasury Bond ETF pays none, and Merck & Co., Inc. is trading nearer its 52-week high, iShares 7-10 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.

IEFMRK
52-Week High
$97.99$131.84
52-Week Low
$92.76$77.60
Market Cap
$321.77B
Sector
Health
Enterprise Value
$368.53B
Dividend Yield
2.61%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares 7-10 Year Treasury Bond ETF

No Aura AI signal available yet.

Merck & Co., Inc.

Merck (MRK) trades at $130.9, up 1.81% today, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $140.36. Recent earnings beats and a 72.97% gross margin highlight strong profitability, while the acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline. The stock faces headwinds from a high P/E ratio of 104.34 and fluctuating cash flows.

The outlook is positive with robust fundamentals and strategic M&A, but valuation concerns and competitive pressures in pharma pose risks. Upside is likely if earnings growth continues, though investors should monitor debt levels and integration of acquisitions.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About iShares 7-10 Year Treasury Bond ETF

The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity of greater than or equal to seven years and less than ten years. The fund will invest at least 80% of its assets in the component securities of the underlying index, and the fund will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index.

Read more on IEF

About Merck & Co., Inc.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.

Read more on MRK